TrialCancer research and treatment2018

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer.

Changhoon Yoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.